The stock of Aspire Biopharma Holdings Inc (NASDAQ: ASBP) has increased by 15.24 when compared to last closing price of 0.27. Despite this, the company has experienced a 13.85% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-24 that Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, today announced the last patient was dosed in its Phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation. Topline results from the study are anticipated by the middle of third quarter of 2025.
Is It Worth Investing in Aspire Biopharma Holdings Inc (NASDAQ: ASBP) Right Now?
ASBP has 36-month beta value of 0.74.
The public float for ASBP is 39.39M, and currently, short sellers hold a 1.71% ratio of that float. The average trading volume of ASBP on July 02, 2025 was 13.29M shares.
ASBP’s Market Performance
The stock of Aspire Biopharma Holdings Inc (ASBP) has seen a 13.85% increase in the past week, with a -27.92% drop in the past month, and a -46.79% fall in the past quarter. The volatility ratio for the week is 17.09%, and the volatility levels for the past 30 days are at 13.43% for ASBP. The simple moving average for the past 20 days is -6.86% for ASBP’s stock, with a -95.28% simple moving average for the past 200 days.
ASBP Trading at -13.39% from the 50-Day Moving Average
After a stumble in the market that brought ASBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.04% of loss for the given period.
Stock Fundamentals for ASBP
The total capital return value is set at 0.33. Equity return is now at value -490.07, with -234.69 for asset returns.
Based on Aspire Biopharma Holdings Inc (ASBP), the company’s capital structure generated -4.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -0.82. The interest coverage ratio of the stock is -0.56.
Currently, EBITDA for the company is -11.65 million with net debt to EBITDA at -0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
To put it simply, Aspire Biopharma Holdings Inc (ASBP) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
